2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neurofibromatosis 1
3
Neurofibromatoses
3
Neurofibroma, Plexiform
2
Neurofibroma
2
Melanoma
2
Glioma
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Vascular Malformations
1
Solid Tumor, Adult
1
Skin Diseases, Vascular
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Oligodendroglioma
1
Neurocytoma
1
Neoplasms, Neuroepithelial
1
NF1
1
Multiple Myeloma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
KRAS Mutant Non-Small Cell Lung Cancer
1
Glioblastoma
1
Ganglioneuroma
1
Ganglioglioma
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Alpelisib
2
mirdametinib
1
Therapeutics
1
Surgical Procedures, Operative
1
Sildenafil Citrate
1
Sclerotherapy
1
Risk Factors
1
Picibanil
1
Injections, Intralesional
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Abnormalities
×
mirdametinib
×
Clear all
NCT05983159
2026-05-05
TARGET-VM
Murdoch Childrens Research Institute
Phase 2
Recruiting
50 enrolled